Broad Pipeline of Differentiated
Product Candidates
to Fight Cancer & Autoimmune Disorders
Enrolling HER2+ Patients with
Metastatic Breast Cancer
in Phase 3 SOPHIA Study
Leading Multispecific Antibody
Technology Platforms
and Protein Engineering Expertise
Breakthrough Biologics,
Life-Changing
Medicines
Fully-integrated, Antibody-based
Development Capabilities,
Including GMP Manufacturing
Focused on Developing
Innovative Medicines
for Patients with Unmet Needs
Breakthrough Biologics,
Life-Changing
Medicines
Overview

We are a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases.

Corporate Fact Sheet

In Memory

We fondly remember Michael Steinmetz, Ph.D., a founding Director of MacroGenics (representing MPM Capital) who passed away in August.  We acknowledge Michael’s leadership in our industry across multiple decades, initially as a research scientist in immunology, then as a leader in pharmaceutical R&D, and eventually as an accomplished venture capital investor.

Latest News

MacroGenics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Read More

MacroGenics Announces the Promotion of Three Executives
Read More

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close